Jump to main content
Jump to site search


Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors

Abstract

In this study, a series of benzimidazole-rhodanine conjugates were designed, synthesized and investigated for their Topoisomerase II (Topo II) inhibition and cytotoxic activities. The results from Topo II-mediated pBR322 DNA relaxation and cleavage assay showed that the synthesized compounds might act as Topo II catalytic inhibitors. Certain compounds displayed potent Topo II inhibition at 10 μM. The cytotoxic activities against Hela, A549, Raji, PC-3, MDA-MB-201, and HL-60 cancer cell lines of these compounds were evaluated. The results indicated that these compounds exhibited strong antiproliferation activity. A good relationship was observed between the Topo II inhibition potency and the cytotoxicity of these compounds. The structure-activity relationship revealed that the electronic effects, the phenyl group, and the rhodanine moiety were particularly important for the Topo II inhibition potency and cytotoxicity.

Back to tab navigation

Supplementary files

Publication details

The article was accepted on 01 Jun 2018 and first published on 02 Jun 2018


Article type: Research Article
DOI: 10.1039/C8MD00278A
Citation: Med. Chem. Commun., 2018, Accepted Manuscript
  •   Request permissions

    Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors

    P. Li, H. Jiang, W. Zhang, Y. Li, C. Dong, H. Chen, K. Zhang and Z. Du, Med. Chem. Commun., 2018, Accepted Manuscript , DOI: 10.1039/C8MD00278A

Search articles by author

Spotlight

Advertisements